<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2 )*
CRESCENDO PHARMACEUTICALS CORPORATION
- --------------------------------------------------------------------------------
(Name of Issuer)
CLASS A COMMON STOCK, PAR VALUE $.01 PER SHARE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
225637 10 7
- --------------------------------------------------------------------------------
(CUSIP Number)
JOSEPH D. LEHRER, ESQ.
10 SOUTH BROADWAY, SUITE 2000, ST. LOUIS, MISSOURI 63102 (314) 241-9090
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
MARCH 3, 1998
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), (f) or (g), check the following
box [ ].
NOTE. Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for
other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------
CUSIP No. 225637 10 7 13D Page 2 of 4 Pages
- -----------------------------------------------------------------------------------------------------------
<S> <C> <C>
1 Names of Reporting Persons/I.R.S. Identification Nos. of Above Persons (entities only)
WOODBOURNE PARTNERS, L.P.
- -----------------------------------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ]
(b) [ ]
- -----------------------------------------------------------------------------------------------------------
3 SEC Use Only
- -----------------------------------------------------------------------------------------------------------
4 Source of Funds (See Instructions)
OO
- -----------------------------------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]
- -----------------------------------------------------------------------------------------------------------
6 Citizenship or Place of Organization
MISSOURI
- -----------------------------------------------------------------------------------------------------------
Number of 7 Sole Voting Power
Shares 862,500, SUBJECT TO THE DISCLAIMER CONTAINED IN ITEM 5.
----------------------------------------------------------------------------
Beneficially 8 Shared Voting Power
Owned by -0-
----------------------------------------------------------------------------
Each 9 Sole Dispositive Power
Reporting 862,500, SUBJECT TO THE DISCLAIMER CONTAINED IN ITEM 5.
----------------------------------------------------------------------------
10 Shared Dispositive Power
Person With
-0-
- -----------------------------------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person
862,500, SUBJECT TO THE DISCLAIMER CONTAINED IN ITEM 5.
- -----------------------------------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]
- -----------------------------------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11)
17.4%
- -----------------------------------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)
PN
- -----------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 3
- --------------------------------------------------------------------------------
CUSIP No. 225637 10 7 13D Page 3 of 4 Pages
- --------------------------------------------------------------------------------
AMENDMENT NO. 2 TO SCHEDULE 13D
-------------------------------
The Reporting Person reported the acquisition of shares of Class A
Common Stock, par value $.01 per share ("Stock"), of Crescendo Pharmaceuticals
Corporation, a Delaware corporation ("Issuer"), 1454 Page Mill Road, Palo Alto,
California 94304, in an initial filing of this Schedule 13D on November 3, 1997,
as amended by Amendment No. 1 to this Schedule 13D on November 17, 1997 . In
this regard, Item 4, Item 5 and Item 6 are hereby amended as follow. All other
items are unchanged from the initial filing.
ITEM 4. Purpose of the Transaction.
The Reporting Person purchased the Stock of the Issuer for general
investment purposes. The Reporting Person may acquire additional shares of the
Stock of the Issuer, based upon its investment decision. It is not contemplated
that any of the acquisitions reported hereunder or any future acquisitions will
result in any change in the present management of the Issuer.
The Reporting Person, General Partner of the Reporting Person and the
person controlling such General Partner have no present plans or proposals which
relate to or would result in:
(a) an extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Issuer or any of
its subsidiaries;
(b) a sale or transfer of a material amount of assets of the
Issuer or any of its subsidiaries;
(c) any change in the present board of directors or management of
the Issuer, including any plans or proposals to change the
number or term of directors or fill any existing vacancies on
the board;
(d) any material change in the present capitalization or dividend
policy of the Issuer;
(e) any other material change in the Issuer's business or
corporate structure;
(f) changes in the Issuer's charter, by-laws or instruments
corresponding thereto or other actions which may impede the
acquisition of control of the Issuer by any person;
(g) causing a class of securities of the Issuer to be delisted
from a national securities exchange or cease to be quoted in
an inter-dealer quotation system of a registered national
securities association;
(h) a class of equity securities of the Issuer becoming eligible
for termination of registration pursuant to Section 12(g)(4)
of the Securities Exchange Act; or
(i) any action similar to those enumerated above.
ITEM 5. Interest in Securities of the Issuer.
(a) Subject to the disclaimer of beneficial ownership hereinafter
set forth, the Reporting Person hereby reports beneficial
ownership of 862,500 shares of Stock in the manner hereinafter
described:
<TABLE>
<CAPTION>
Percentage of
Relationship to Number of Outstanding
Shares Held in Name of Reporting Person Shares Securities
---------------------- ---------------- --------- -------------
<S> <C> <C> <C>
Woodbourne Partners, L.P. Reporting Person 862,500 17.4%
</TABLE>
The foregoing percentages assume that the Issuer has 4,963,615 shares of
Stock outstanding.
<PAGE> 4
- --------------------------------------------------------------------------------
CUSIP No. 225637 10 7 13D Page 4 of 4 Pages
- --------------------------------------------------------------------------------
AS PROVIDED IN S.E.C. REGULATION Section 240.13d-4, THE REPORTING PERSON
HEREBY DECLARES THAT THIS STATEMENT SHALL NOT BE CONSTRUED AS AN ADMISSION THAT
IT IS, FOR THE PURPOSES OF SECTION 13(d) OR 13(g) OF THE SECURITIES EXCHANGE
ACT, THE BENEFICIAL OWNER OF THE SECURITIES COVERED BY THIS STATEMENT.
(b) Subject to the above disclaimer of beneficial ownership, for each
person named in paragraph (a), the number of shares as to which
there is sole power to vote or direct the vote, shared power to vote
or direct the vote, sole power to dispose or direct the disposition,
or shared power to dispose or direct the disposition, is the same as
in paragraph (a).
(c)
<TABLE>
<CAPTION>
Net Price
Number Per Transaction
Purchase in the Name of Date of Shares Share Made Through
----------------------- -------- --------- --------- --------------
<S> <C> <C> <C> <C>
Woodbourne Partners, L.P. 12/10/97 20,000 11.4375 Jefferies & Co.
Woodbourne Partners, L.P. 2/4/98 25,000 11.75 Jefferies & Co.
Woodbourne Partners, L.P. 2/6/98 12,500 11.625 Jefferies & Co.
Woodbourne Partners, L.P. 2/10/98 5,000 11.6875 Jefferies & Co.
Woodbourne Partners, L.P. 2/27/98 10,000 11.75 Jefferies & Co.
Woodbourne Partners, L.P. 3/3/98 30,000 11.75 Jefferies & Co.
</TABLE>
(d) Not applicable.
(e) Not applicable.
ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect
to Securities of the Issuer.
None.
After reasonable inquiry, and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
WOODBOURNE PARTNERS, L.P.,
by its General Partner, CLAYTON
MANAGEMENT COMPANY
/s/ John D. Weil
-------------------------------
John D. Weil, President
March 6, 1998
